Cover Story
In the next few weeks, FDA will announce its decision on Novartis's Zarxio, a granulocyte-colony stimulating factor biosimilar to Amgen's Neupogen.
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials
- My bad: I left out Fox Chase
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- NCI creates Cancer Equity Leaders group to improve cancer health equity
- Edward Copeland, surgeon and breast cancer expert, dies at 86